Your browser doesn't support javascript.
loading
Ivabradine in Cardiovascular Disease Management Revisited: a Review.
Chen, Christopher; Kaur, Gurleen; Mehta, Puja K; Morrone, Doralisa; Godoy, Lucas C; Bangalore, Sripal; Sidhu, Mandeep S.
Afiliación
  • Chen C; Division of Cardiovascular Medicine, University of California Davis, Sacramento, CA, USA.
  • Kaur G; Albany Medical College, Albany, NY, USA.
  • Mehta PK; Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.
  • Morrone D; Division of Cardiology, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
  • Godoy LC; Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Canada.
  • Bangalore S; Instituto do Coracao (InCor), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
  • Sidhu MS; Division of Cardiology, New York University Grossman School of Medicine, New York, NY, USA.
Cardiovasc Drugs Ther ; 35(5): 1045-1056, 2021 10.
Article en En | MEDLINE | ID: mdl-33411112
Ivabradine is a unique agent that is distinct from beta-blockers and calcium channel blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. Ivabradine is a use-dependent inhibitor targeting the sinoatrial node. It is approved for use in the United States as an adjunct therapy for heart rate reduction in patients with heart failure with reduced ejection fraction. In this scenario, ivabradine has demonstrated improved clinical outcomes due to reduction in heart failure readmissions. However, there has been conflicting evidence from prospective studies and randomized controlled trials for its use in stable ischemic heart disease regarding efficacy in symptom reduction and mortality benefit. Ivabradine may also play a role in the treatment of patients with inappropriate sinus tachycardia, who often cannot tolerate beta-blockers and/or calcium channel blockers. In this review, we highlight the evidence for the nuances of using ivabradine in heart failure, stable ischemic heart disease, and inappropriate sinus tachycardia to raise awareness for its vital role in the treatment of select populations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Cardiovasculares / Enfermedades Cardiovasculares / Ivabradina Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Cardiovasc Drugs Ther Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Cardiovasculares / Enfermedades Cardiovasculares / Ivabradina Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Cardiovasc Drugs Ther Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos